Our top pick for
Federated Hermes Inc is an asset management business based in the US. Federated Hermes shares (FHI) are listed on the NYSE and all prices are listed in US Dollars. Federated Hermes employs 2,000 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$33.16|
|52-week range||$19.97 - $34.74|
|50-day moving average||$32.03|
|200-day moving average||$32.27|
|Wall St. target price||$33.79|
|Dividend yield||$1.08 (3.29%)|
|Earnings per share (TTM)||$3.11|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||0.42%|
|1 month (2021-09-22)||10.13%|
|3 months (2021-07-22)||3.40%|
|6 months (2021-04-22)||12.03%|
|1 year (2020-10-22)||33.60%|
|2 years (2019-10-22)||4.84%|
|3 years (2018-10-22)||45.82%|
|5 years (2016-10-21)||20.85%|
Valuing Federated Hermes stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Federated Hermes's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Federated Hermes's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Federated Hermes shares trade at around 11x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Federated Hermes's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.1921. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Federated Hermes's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Federated Hermes's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $436.5 million.
The EBITDA is a measure of a Federated Hermes's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1.4 billion|
|Operating margin TTM||29.51%|
|Gross profit TTM||$944.9 million|
|Return on assets TTM||12.8%|
|Return on equity TTM||23.35%|
|Market capitalisation||$3.2 billion|
TTM: trailing 12 months
There are currently 3.2 million Federated Hermes shares held short by investors – that's known as Federated Hermes's "short interest". This figure is 0.2% up from 3.2 million last month.
There are a few different ways that this level of interest in shorting Federated Hermes shares can be evaluated.
Federated Hermes's "short interest ratio" (SIR) is the quantity of Federated Hermes shares currently shorted divided by the average quantity of Federated Hermes shares traded daily (recently around 470865.07246377). Federated Hermes's SIR currently stands at 6.9. In other words for every 100,000 Federated Hermes shares traded daily on the market, roughly 6900 shares are currently held short.
However Federated Hermes's short interest can also be evaluated against the total number of Federated Hermes shares, or, against the total number of tradable Federated Hermes shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Federated Hermes's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Federated Hermes shares in existence, roughly 30 shares are currently held short) or 0.0366% of the tradable shares (for every 100,000 tradable Federated Hermes shares, roughly 37 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Federated Hermes.
Find out more about how you can short Federated Hermes stock.
Dividend payout ratio: 67.31% of net profits
Recently Federated Hermes has paid out, on average, around 67.31% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.27% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Federated Hermes shareholders could enjoy a 3.27% return on their shares, in the form of dividend payments. In Federated Hermes's case, that would currently equate to about $1.08 per share.
Federated Hermes's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Federated Hermes's most recent dividend payout was on 12 August 2021. The latest dividend was paid out to all shareholders who bought their shares by 4 August 2021 (the "ex-dividend date").
Federated Hermes's shares were split on a 3:2 basis on 17 July 2000. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Federated Hermes shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Federated Hermes shares which in turn could have impacted Federated Hermes's share price.
Over the last 12 months, Federated Hermes's shares have ranged in value from as little as $19.9732 up to $34.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Federated Hermes's is 1.0831. This would suggest that Federated Hermes's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Federated Hermes, Inc. is a publicly owned asset management holding company. Through its subsidiaries, the firm provides its services to individuals, including high net worth individuals, banking or thrift institutions, investment companies, pension and profit sharing plans, pooled investment vehicles, charitable organizations, state or municipal government entities, and registered investment advisors. Through its subsidiaries, it manages separate client-focused equity, fixed income, balanced and money market mutual funds along with separate client-focused equity, fixed income, money market, and balanced portfolios. Through its subsidiaries, the firm invests in the public equity and fixed income markets across the globe. It invests in growth and value stocks of small-cap, mid-cap, and large-cap companies. The firm makes its fixed income investments in ultra-short, short-term, and intermediate-term mortgage-backed, U.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.